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direct and indirect healthcare costs of type 2 diabetes in Austria. Methods: A 
burden of disease study, which evaluates all kinds of disease burden, like costs, 
quality adjusted life years (QALYs) and disability adjusted life years (DALYs) lost, 
was conducted. This study uses a prevalence-based bottom-up approach and pro-
jects costs over the time horizon of one year. Data were collected via literature 
review, published list prices and hospital records. Costs from published sources 
were used from the societal perspective. The direct costs include hospital, treat-
ment and physician consultation costs. Indirect costs cover patient care giver costs 
as well as work absenteeism. Results: The average costs per year of a Diabetes 
Type 2 are 3,242.91 EUR. Inpatient care is a major contributor to costs, accounting 
for 81% of total costs while drug costs account for an average of 14%. The estimated 
total direct annual cost for all patients diagnosed with type 2 diabetes is 1.2 billion 
EUR. This represents a share of 3.3% of the country´s total healthcare expendi-
tures. The average annual indirect costs for patients with diabetes mellitus type 
2 amounts to 781 million EUR. Compared to the healthy population, the diabetes 
mellitus type 2 population have utility decrements of 251,974 QALYs. Moreover 
type 2 diabetes patients will lose 19,853 DALYs within one year. ConClusions: 
Type 2 diabetes mellitus is a common disease and the prevalence is expected to 
increase considerably in the future. The findings of this study demonstrate the 
high economic import of the disease.
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objeCtives: Although type 2 diabetes (T2DM) has been globally recognised as a 
major public health issue with substantial economic implications, its quantita-
tive impact in some geographical regions is not well documented. This study 
aimed to describe the health care resource utilisation (HCRU) associated with 
T2DM in Africa, Middle East, South Asia, Eurasia and Turkey. Methods: Cross-
sectional data from 8,156 patients recruited across four geographical regions 
(18 countries) was collected as part of the 5th wave of the IDMPS (2011–2012). 
Mean (SD) annual levels of different types of HCRU were estimated and negative 
binomial regression was undertaken to identify drivers of HCRU by region and 
country. Results: Estimated HCRU showed that patients in South Asia (n= 1,195), 
Eurasia (n= 1,843), Africa (n= 2,220) Middle East (n= 2,065) and Turkey (n= 842) expe-
rienced a mean (SD) of 0.4 (1.5), 1.7 (4.1), 0.6 (1.9), 0.3 (1.2) and 1.3 (2.7) hospitalisa-
tions annually. The mean (SD) annual number of diabetes-related inpatient days 
was 1.5 (6.8), 16.0 (30.0), 4.7 (22.7), 1.1 (6.1) and 10.8 (34.3) respectively. The mean 
(SD) annual number of sick days due to diabetes for the same regions were 4.6 
(19.7), 17.5 (35.4), 11.6 (44.4), 1.4 (6.8) and 8.0 (34.4). Presence of macrovascular 
complications was a key driver of incidence of hospitalisations [Incidence Rate 
Ratio - IRR (CI 95%)] in South Asia [3.4 (1.4–8.5)], Eurasia [1.4 (1.1–1.8)], Africa [3.9 
(2.1–7.3)], Middle East [8.9 (4.6–15.7)] and Turkey [2.9 (1.8–4.6)]. Microvascular com-
plications were associated with increased risk of hospitalisations in all regions 
with IRRs (CI 95%) of 3.5 (1.8 – 7.0), 3.4 (2.2 – 5.1), 3.7 (2.2 – 5.1), 1.7 (1.0 – 2.9) 
and 3.4 (2.2 – 5.1) respectively. ConClusions: Results of this study demon-
strate that in South Asia, Eurasia, Africa, Middle East and Turkey, development 
of micro and macrovascular complications are key drivers for economic burden 
of T2DM.
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objeCtives: Diabetes imposes huge social and economic impact on nations. 
However, information on the costs of treating and managing diabetes in develop-
ing countries is limited. The aim of this study was to estimate healthcare use and 
expenditure for diabetes in Bangladesh. Methods: We conducted a matched 
case-control study between January and July 2014 among 591 adults with diag-
nosed diabetes mellitus (DMs) and 591 age, sex, and residence matched persons 
without diabetes mellitus (non-DMs). We recruited DMs from consecutive patients 
and non-DMs from accompanying persons in BIHS hospital in Dhaka, Bangladesh. 
We estimated the impact of diabetes on healthcare use and expenditure by calcu-
lating ratios and differences between DMs and non-DMs and tested for statistical 
difference using t-tests. Results: DMs had two times more days of inpatient 
treatment, 1.3 times more outpatient visits, and 9.7 times more medications 
than non-DMs (all p< 0.005). The total annual per capita expenditure on medical 
care was 6.12 times higher for DMs than non-DMs (USD 635 vs. 104, respectively). 
Among DMs, 9.8% reported not taking any antidiabetic medications, 46.4% took 
metformin, 38.7% sulphonylurea, 40.8% insulin, 38.7% any antihypertensive medi-
cation, and 14.2% took anti-lipids over the preceding 3 months. ConClusions: 
Diabetes significantly increases healthcare use and expenditure and is likely to 
impose a huge economic burden on the healthcare systems in Bangladesh. The 
study highlights the importance of prevention and optimum management of dia-
betes in Bangladesh, and other developing countries, to gain a strong economic 
incentive through implementing multi-sectoral approach and cost-effective pre-
vention strategies.
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literature, there is little if any attempt to quantify it. We aim to quantify the dif-
ference between the efficacy and effectiveness of Metformin in terms of reduc-
ing HbA1c in patients with type-2-diabetes. Methods: First, a systematic review 
was carried out to identify relevant randomized controlled trials (RCTs) and non-
interventional studies (NIS). CENTRAL, MEDLINE (via PubMed) and clinicaltrials.
gov were searched for relevant articles published within the last 20 years. RCTs 
and NIS which evaluated the treatment effects of Metformin in adult patients with 
type-2-diabetes and analyzed glycaemic control by means of change in HbA1c value 
were included. Studies in which Metformin was used as a concomitant antidia-
betic, studies with a study period of less than three months and studies analyzing 
subpopulations were excluded from further research. Only German and English 
papers were eligible. Second, mean values of HbA1c reduction were aggregated in 
a meta-analysis using a random-effects model. Study heterogeneity was assessed 
by the I2-parameter. To test for publication bias we used funnel plots. Results: In 
total 1151 articles were identified. 21 RCTS and 6 NIS were included in the quantita-
tive analysis. Overall HbA1c was reduced by 1.012% (95%-CI: -1.186%; -0.839%). I2 
was 99.911% (RCTs: 99.932; NIS: 97.769) indicating high heterogeneity. The compari-
son of the two settings resulted in a small difference of 0.130% in HbA1c decrease 
between RCTs (-0.953%; 95%CI: -1.188%, -0.717%) and NIS (-1.083%; 95% CI: -1.34%, 
-0.826%). ConClusions: The results of our analysis indicate that the often-men-
tioned gap between clinical studies and real-world application does not exist in the 
treatment of type-2-diabetes with Metformin.
PDB122
analysIs of the consuMPtIon anD PharMacoeconoMIc evaluatIon 
of usIng DIfferent forMulatIons of alPha-lIPoIc acID In the 
PharMaceutIcal Market of ukraIne
Kyrychenko O, Iakovlieva L, Mishchenko O, Bezditko N, Gerasymova O
National University of Pharmacy, Kharkiv, Ukraine
objeCtives: According to the National Unified Clinical Protocol of Primary and 
Secondary (Specialized) Medical Care, for type 2 diabetes mellitus preparations of 
alpha-lipoic acid (ALA) at high doses are recommended as a pathogenetic therapy 
of painful diabetic neuropathy. The pharmaceutical market of Ukraine proposes 
2 oral formulations of ALA preparations: standard and HRF (High Release form). 
Pharmacokinetic studies [MMW Spezial, Münch. med. Wschr. 1999, 141: page 2] 
showed that comparing with the standard formulation HRF of ALA reduces the 
inter-individual variability in absorption by 58% thus ensuring optimal absorption 
in most patients. The objective of the study was to assess the consumption of oral 
formulations of ALA preparations in the pharmaceutical market of Ukraine and to 
conduct pharmacoeconomic evaluation. Methods: The consumption of 2 oral for-
mulations of ALA preparations was assessed in indicator DDDs/1000 inhabitants/day 
(DIDs). To conduct the pharmacoeconomic evaluation, results of pharmacokinetic 
studies were used [MMW Spezial, Münch. med. Wschr. 1999, 141: page 2]. Results: 
In 2013, the amount of consumption of ALA preparations in the pharmaceutical 
market of Ukraine was 1.79 DIDs. The portion of HR formulation accounts for 5.35% 
of the total amount of consumption and the consumption of the standard oral 
formulation of ALA preparations accounts for 94.65%, respectively. According to 
authors of the study, the indicator of the inter-individual variability in absorption 
was 22% for HRF and 59% – for standard ALA formulation. Thus NNT indicator is 
1/0.37 = 2.7. Calculating the cost of achieving a therapeutically effective plasma 
level in 1 patient on the NNT indicates that the achievement of a therapeutic level 
in the blood plasma needs 2.7 times more costs when administering the standard 
ALA formulation compared to HRF. ConClusions: HR formulation of ALA has a 
higher cost effectiveness compared to the standard oral formulation, which makes 
it more efficient to use.
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objeCtives: To assess medical technologies in order to increase efficiency and 
reduce the cost of thyroid disease treatment. Methods: We made the retrospective 
analysis of 81 patients’s medical records with hypothyroidism that were hospital-
ized to the endocrinology department of Ternopil University Hospital (Jan-Dec 2012). 
The cost of replacement therapy with levothyroxine drugs, which were preferred 
in practice, was analyzed. We also checked the appropriateness of diagnostics and 
specialist consultations according to the Protocol of medical care for patients with 
endocrine system disorders. Results: The result of retrospective analysis of 81 
patients’s medical records with hypothyroidism showed that all patients received 
replacement therapy by levothyroxine. Among them 74 patients were treated with 
drugs of Ukrainian production while 7 patients were taking medicine of foreign 
manufacturer. The cost of pharmacotherapy with foreign medicines was 125% 
more expensive compare to Ukrainian drugs. When comparing diagnostics and 
specialists consultations with a Protocol of medical care for patients with endo-
crine system disorders we have established compliance. However, given the preva-
lence of complications of underlying disease by cardiovascular system disorders 
(in 100% of patients), we consider it necessary to add cardiologist consultation to 
Protocol. ConClusions: It is advisable to use domestic drugs in pharmacotherapy 
of hypothyroidism. Cardiologist consultation should be added to Protocol of medical 
care for patients with hypothyroidism.
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objeCtives: Type 2 diabetes mellitus affects 358,267 individuals in Austria and 
exerts a substantial economic burden on patients, healthcare systems and society. 
The main objective of this study is to analyse the burden of disease as well as the 
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received an added benefit, in France all drugs assessed received a positive SMR 
and no improvement in actual benefit.
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objeCtives: To evaluate the prevalence and patterns of CAM use among dia-
betes patients in Pakistan. In addition, the study also focused on the perceived 
effectiveness of CAM over conventional therapies, information seeking behavior 
and CAM disclosure to healthcare providers. Methods: A prospective, cross-
sectional and self-administered questionnaire based study was conducted in 
tertiary care public hospitals in Pakistan. A prevalence based sample of 350 dia-
betes patients attending the tertiary hospital in Punjab, Pakistan were selected 
for the study. All obtained data were analyzed using descriptive and inferential 
statistics. Results: Overall, 327 questionnaires were completed and included in 
the analysis, showing that 52.8% of diabetics had used CAM, with most (62.4%) 
believing that CAM therapies assist body’s natural forces to heal. CAM usage 
was significantly associated with gender (P= 0.001), level of education (P= 0.001), 
employment status (P= 0.03) and monthly income (P< 0.001). ConClusions: 
Diabetes treatment and management requires compliance to effective therapies 
at early stages. Healthcare providers should engage diabetics in an open non-judg-
mental dialogue to ascertain better understanding of diabetes and its management 
options.
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objeCtives: Since 2011, an early benefit assessment is required for all new drugs 
being launched in Germany. Evidence submitted by pharmaceutical companies 
in dossiers is assessed by the Institute for Quality and Efficiency in Health Care 
(IQWiG) and subsequently appraised by the German Federal Joint Committee (FJC). 
The exact determination of the patient target population plays an important role 
for subsequent price negotiations. In diabetes mellitus type 2 the size of target 
population varies considerably between dossiers. Our aim was to explore the 
reasons for these differences. Methods: We analyzed 20 dossiers with drugs for 
diabetes mellitus type 2 published between January 2012 and May 2015. Details 
regarding the estimation of the target population were extracted and compared. 
Based on the extractions a criteria list was developed to categorize possible rea-
sons for different sizes of the target population. Results: The estimations of the 
target population were mainly based on secondary data analyses of drug prescrip-
tions. The methods and assumptions used to analyze these data varied widely. 
Important reasons for differences in the estimations are the kind of database, the 
time frame, the operationalization of diabetes patients, the specification of the 
target population, the type of contraindications, the consideration of currently 
undetected patients, the mode of extrapolation to the overall population, and the 
portion of statutory health insurance patients. We could not identify one reason 
that could explain most of the deviations in the size of the target population. 
Several reasons seem to interact and it was not possible to determine the direc-
tion or size of the effect. ConClusions: There is a strong need for more detailed 
descriptions of the methods and databases used in the dossiers to estimate the 
size of the target populations. A harmonization of the methods seems to be help-
ful to reduce the variation.
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objeCtives: Modifiable risk factors such as trio Hs are major contributor to the 
disease burden in Malaysia. Heart disease is number one leading cause of death 
in the country and individuals with diabetes are two to four times more likely 
to develop heart disease or stroke relative to those without diabetes. In view of 
severe multifold outcome caused by trio Hs, we aim to examine the prevalence of 
undiagnosed trio Hs and management of these risk factors among participants 
who had previously detected with these conditions. Methods: We retrospec-
tively performed secondary data analysis on random selective samples from 
Pfizer Care-a-Van community health screening which was established in year 
1999. Health screenings were conducted in mobile examination centers across 
the country by a team of registered physician, nurses, and volunteers along with 
various NGO partners. Standardized screening forms were used to collect demo-
graphic data and screening results. Participants with abnormal screening results 
will be referred to government clinics or hospitals for further tests and/or treat-
ment. Descriptive analysis was performed using Stata 13. Results: A total of 
7601 subjects were available for analysis from 2003 till 2014. Over half (58.4%) of 
the screening participants were female aged 45.8 years (SD, 14.4). 13.3% had been 
previously diagnosed with hyperlipidemia, while 10.6% and 13.1% were diabetic 
and hypertensive. Undiagnosed hyperlipidemia was reported at 56.5%, followed 
by hyperglycemia (32.5%) and hypertension (17.8%). Almost half (49.9%) of hyper-
tensive and 59.2% hyperlipidemia subjects failed to achieve target blood pres-
sure and cholesterol level whereas only 38.2% diabetic had their blood glucose 
under control. ConClusions: Multiple risk factors pose a significant burden 
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objeCtives: The aim of this study was to assess the burden of peripheral arte-
riopathy (PA) in diabetic patients. Methods: Eligible patients were identified 
through a data warehouse (DENALI), which matches clinical and economic data 
of about 9.9 million individuals of Lombardy, a northern Italian region which 
represent 16.4% of the Italian population. The study population was made of all 
individuals over 40 with a diagnosis of diabetes who during the period 1-1-2002 
to 31-12-2009 had an hospital admission (index event) attributable to PA disease. 
The identified individuals were followed-up from the index event to a maximum 
of 7 years. We evaluated demographic characteristics of the study population 
and costs (hospitalizations, drugs and outpatient examinations/visits) from the 
National Health Service’s perspective. Results: During the observational period 
18,344 subjects (5% of the diabetic source population) had at least one hospital 
admission of interest. Median age (min-max) at the index date was 73(40-102) 
and 31% of the study population had a Charlson comorbidity index higher than 3. 
The overall mortality was 11.3 deaths every 100 patient-years (95%C.I., 11.1-11.6). 
Forty-four percent of the study population had at least one procedure among 
vascularization, minor and major amputation. Mean cost and corresponding 95% 
C.I. (€ /patient-year) for PA diabetic patients was 14,085(12,344-16,400) in the index 
year and around 7,000 in the following periods of observation. Hospitalizations 
represented the driver of total costs. ConClusions: This study attempted to 
describe the epidemiologic and economic burden of diabetes patients with PA 
complications, showing the relevance of related epidemiologic and economic 
aspects.
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objeCtives: Dipeptidyl peptidase-4 (DPP-4) inhibitors were recently approved 
in the US. The objective is to evaluate the prescribing behavior of traditionally 
used type 2 diabetic medications and the newer DPP-4 inhibitors. Methods: 
This cross-sectional study used data from the 2006-2010 National Ambulatory 
Medical Care Survey (NAMCS) and employed the Eisenberg model of physi-
cian decision making. The dependent variable was the use of DPP-4 inhibitors. 
The following independent variables were determined based on the Eisenberg 
model: age, gender, race/ethnicity, insurance type, primary care physician, 
practice region, metropolitan status, practice setting, previous physician office 
visits, and the type of diabetes medication, and survey year. Multivariate logis-
tic regressions were used for analyses. Results: The estimated population 
size was 535,158,796 patients with type 2 diabetes, and 3.85% of them were 
prescribed DPP-4 inhibitors. The most frequently used diabetic medication 
group was biguanides (metformin) (26.1%), followed by sulfonylurea (17.8%). 
The use of other diabetes medication was highly associated with the likelihood 
of the use of DPP-4 inhibitors. Patients who were prescribed sulfonylurea were 
approximately twice and patients who were prescribed biguanides (metformin) 
were approximately three times more likely to be prescribed DPP-4 inhibitors 
(OR = 1.62; p = 0.009 and OR = 2.96; p < 0.001, respectively). The likelihood of 
the use of DPP-4 inhibitors was also increased with patients receiving insulin 
(OR = 1.62; p = 0.009). ConClusions: The prescribing of the DPP-4 inhibi-
tors increased with current use of biguanides (metformin), sulfonylureas, and 
insulin.
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objeCtives: In recent years new type II diabetes (T2D) therapies were launched 
and evaluated by the different market access authorities in France and Germany. 
Decisions were mostly controverse especially in Germany why a comparison 
with comparable health care systems is required. The international Prismaccess 
database includes all evaluations and decisions in France and Germany, besides 
other global authorities. Methods: All decisions for new T2D therapies in 2014 
and 2015 which were evaluated by the authorities in France and Germany were 
systematically searched for. A comparison was executed with a focus on reim-
bursement decision, basis of decision, acceptance of submitted clinical endpoints, 
study designs, and comparators. Results: In total there were 9 new therapies 
evaluated in France by the Transparency Commission. The level of added benefit 
differed mainly dependent on the combination or monotherapy analyses with 
other OADs and/or insulin. Five out of 9 drugs had all anti-diabetic drugs as com-
parators without specific distinction and 8 out of 9 drugs were rated with an ASMR 
versus the therapeutic strategy. Even though that all therapies received a substan-
tial SMR, most also had some insufficient ratings with respect to monotherapy. All 
therapies received an ASMR rating of V (no added benefit). In Germany the G-BA 
evaluated seven drugs. Six therapies received a non-added benefit. Albiglutide 
was the only therapy receiving an added benefit (non-quantifiable benefit). All 
comparators were against other active diabetes drugs. One exception was the 
assessment of canagliflozin in combination with metformin which was not only 
compared against drugs but against therapeutic strategies. ConClusions: Using 
the Prismaccess database the analysis shows that there are key differences in 
the assessment of the same clinical data in T2D. In Germany only one therapy 
